SlideShare une entreprise Scribd logo
1  sur  2
Télécharger pour lire hors ligne
New FDA Draft Guidance on Mobile Medical Apps
Rebecca Johnson, Digital Integration & Innovation
July 2011


Top-Level Points                             Summary
                                             On July 19, 2011, the U.S. Food and Drug Administration (FDA) issued a new draft
   The FDA issued guidance on
                                             guidance detailing how the regulatory body defines, classifies and regulates “mobile
    mobile apps for medical use
                                             medical apps.” The new guidance expands upon the FDA’s previous definition of a
   The FDA has established a two-           medical device to include what the FDA defines as mobile medical apps. The FDA
    part definition of a mobile              believes these mobile medical apps, which are increasingly common, pose the same
    medical app                              risks to patients as those posed by medical devices (e.g. EEG and MRI) and that the
                                                                                                         1
                                             FDA is therefore required to regulate mobile medical apps. As with all FDA draft
   The FDA classifies three specific        guidances, these guidelines do not establish legally enforceable responsibilities but
    subsets of mobile medical apps           rather describe the regulatory agency’s current thinking and recommendations on
    (based strongly on the app’s             the subject matter. Nevertheless, these guidelines should be taken seriously.
    intended use) as medical devices
   Mobile medical apps that classify        Key Information
    as medical devices should follow         The FDA’s “Draft Guidance for Industry and Food and Drug Administration Staff –
    FDA guidance and regulations for         Mobile Medical Applications” can be summarized into three main sections that state
    medical devices                          the FDA’s position on:
                                                  Definition of a Mobile Medical App
   The agency has listed specific
    types of mobile apps it will not be           Scope of FDA Regulation Over Mobile Medical Apps
    monitoring                                    FDA Mobile Medical App Regulations and Controls

   The FDA realizes these new
                                             In the new documentation, the FDA provides its definition of a mobile application
    guidelines may cause some
                                             (mobile app) as “a software application that can be executed (run) on a mobile
    confusion, and it encourages
                                             platform, or a web-based software application that is tailored to a mobile platform
    manufacturers of mobile medical
                                             but is executed on a server.” With this broad app definition in place, the FDA then
    apps to contact the Agency to
                                             lays out a two-part definition for a “mobile medical app” that it will use to evaluate
    determine the classification of
                                             what apps fall under its oversight.
    their mobile app
   If needed, the FDA will expand                  1.   The mobile medical app must meet the FDA definition of a device: “an
    its current definition of a mobile                   instrument, apparatus, implement, machine, contrivance, implant, in vitro
    medical app and apply                                reagent… intended for use in the diagnosis or the cure, mitigation,
    regulations per this new                             treatment, or prevention of disease, or to affect the structure or any
                                                                                       2
    definition                                           function of the body of man.”
                                                    2.   The mobile medical app must be either “used as an accessory to a regulated
   In future guidelines, the FDA will
                                                         medical device” or “transform a mobile platform into a regulated medical
    be addressing issues of wireless                              3
                                                         device.”
    safety, quality systems and
    clinical decision support
                                             Most mobile apps will meet the first definitional requirement, as the FDA already
                                             considers application software a form of device. Therefore, the real qualifier will be
                                             the mobile app’s intended use, which the FDA states can be found in the app’s
                                             labeling claims, advertising materials, or in oral or written statements by
                                             manufacturers or their representatives.

                                             However, the FDA will only be applying its regulatory oversight to three types of
                                             mobile medical apps, because it believes these apps pose the same or similar risk to
                                             the public health as currently regulated medical devices. The three types of apps,
                                             listed below, are based on the app’s intended use.


                                             1
                                               “Draft Guidance for Industry and Food and Drug Administration Staff – Mobile Medical Applications”
                                             (page 5)
                                             2
                                               “Federal Food, Drug and Cosmetic Act (FD&C Act)” - Section 201(h)
                                             3
                                               “Draft Guidance for Industry and Food and Drug Administration Staff – Mobile Medical Applications”
                                             (page 7)

                                                         Pg. 1
1. Apps that connect to a medical device for the purpose of A) controlling the device, or B) displaying, storing,
                  analyzing or transmitting patient-specific medical device data (e.g. an app that controls the delivery of insulin on
                  an insulin pump by transmitting signals to the pump)

               2. Apps that transform the mobile platform into a medical device by using attachments, display screens or sensors or
                  by including functionalities similar to those of currently regulated medical devices (e.g. an app that allows doctors
                  to monitor brain activity by attaching EEG sensors to a mobile device)

               3. Apps that allow the user to input patient-specific information and — using formulae or processing algorithms —
                  output a patient-specific result, diagnosis or treatment recommendation to be used in clinical practice or to assist
                  in making clinical decisions (e.g. an app that provides a questionnaire for collecting patient-specific lab results and
                  computes the prognosis of a particular condition)

If a mobile medical app falls into one of the above categories, its manufacturers are required to follow the medical device
regulations established by the FDA. These medical device regulations and controls are broken up into three classifications (Class I,
Class II and Class II). A mobile medical app’s classification will determine, among other things, the type of pre-marketing
submission/application required for FDA clearance to market.

In addition to stating the definition of a mobile medical app and what types of mobile medical apps it will regulate, the FDA has also
defined categories of mobile apps it does not consider mobile medical apps and that are therefore not subject to draft guidance.
This list includes apps that:

        Are electronic “copies” of medical textbooks, teaching aids, or reference materials (e.g. an electronic version of the
         Physician’s Desk Reference or reference flash cards or slideshows of common conditions)
        Are solely used to log, record, track, evaluate or make decisions or suggestions related to general health, lifestyle and
         wellness (e.g. dietary tracking logs, appointment reminders, exercise suggestions, etc.)
        Automate general office operations with functionalities that include billing, inventory, appointments or insurance
         transactions (e.g. apps that determine billing codes or automate functions such as collecting patient histories or that enable
         insurance claims data collection)
        Are generic aids that assist users but are not commercially marketed for a specific medical indication (e.g. apps that use the
         mobile platform for recording audio or note-taking)
        Perform the functionality of an electronic health record system or personal health record system

Implications and Action Items

        Apps Already in Market: Review the FDA draft guidance closely. Determine if your app meets the FDA mobile medical app
         definition. If it does, work with your legal and regulatory teams to determine if it falls under the FDA’s regulatory oversight
         as a medical device and will need to follow the medical device regulations established by the FDA.
        Apps Currently in Development: Review the FDA draft guidance closely. Discuss with your regulatory and legal
         departments the potential impact these new regulations may have on your app with a particular eye to timelines, budget
         and functionality.
        Planning an App: Review the FDA draft guidance closely. Ascertain if your proposed app meets the FDA mobile medical app
         definition. If it will be under the FDA’s regulatory oversight, then follow the medical device regulations established by the
         FDA.
        Potential for More Guidelines: While the FDA has been very specific with its definition of what is and isn’t a mobile medical
         app, in the draft guidance the Agency will continue to monitor the performance of other mobile apps that are outside this
         guidance and determine whether additional or different actions are necessary to protect the public health.

For more insights into applying FDA regulations to digital marketing, see: http://rtcrm.com/whitepapers/




                                                        Pg. 2

Contenu connexe

Plus de RTC

RTC Google Knowledge Graph POV June 2012
RTC Google Knowledge Graph POV June 2012RTC Google Knowledge Graph POV June 2012
RTC Google Knowledge Graph POV June 2012RTC
 
RTC Perspectives, May 2012: Thank You, Star Trek
RTC Perspectives, May 2012: Thank You, Star TrekRTC Perspectives, May 2012: Thank You, Star Trek
RTC Perspectives, May 2012: Thank You, Star TrekRTC
 
RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012
RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012
RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012RTC
 
RTC POVs: FDA Warning Letter for Copaxone, March 2012
RTC POVs: FDA Warning Letter for Copaxone, March 2012RTC POVs: FDA Warning Letter for Copaxone, March 2012
RTC POVs: FDA Warning Letter for Copaxone, March 2012RTC
 
RTC POVs: FDA Guidance on TV Ad Pre-Dissemination Review
RTC POVs: FDA Guidance on TV Ad Pre-Dissemination ReviewRTC POVs: FDA Guidance on TV Ad Pre-Dissemination Review
RTC POVs: FDA Guidance on TV Ad Pre-Dissemination ReviewRTC
 
RTC Perspectives: February 2012
RTC Perspectives: February 2012RTC Perspectives: February 2012
RTC Perspectives: February 2012RTC
 
FDA Warning Letters: Dr. Reddy's Labs, January 2012
FDA Warning Letters: Dr. Reddy's Labs, January 2012FDA Warning Letters: Dr. Reddy's Labs, January 2012
FDA Warning Letters: Dr. Reddy's Labs, January 2012RTC
 
Dii POV: FDA Off-Label Guidance
Dii POV: FDA Off-Label GuidanceDii POV: FDA Off-Label Guidance
Dii POV: FDA Off-Label GuidanceRTC
 
Internet Radio for Marketers
Internet Radio for MarketersInternet Radio for Marketers
Internet Radio for MarketersRTC
 
Patient Support Landscape
Patient Support LandscapePatient Support Landscape
Patient Support LandscapeRTC
 
FDA Warning Letters: Otsuka, October 2011
FDA Warning Letters: Otsuka, October 2011FDA Warning Letters: Otsuka, October 2011
FDA Warning Letters: Otsuka, October 2011RTC
 
FDA Warning Letter: Busulfex Site
FDA Warning Letter: Busulfex SiteFDA Warning Letter: Busulfex Site
FDA Warning Letter: Busulfex SiteRTC
 
Strategy and Insights Brainstorming Guide
Strategy and Insights Brainstorming GuideStrategy and Insights Brainstorming Guide
Strategy and Insights Brainstorming GuideRTC
 
RTCRM POVs: Facebook Changes, September 2011
RTCRM POVs: Facebook Changes, September 2011RTCRM POVs: Facebook Changes, September 2011
RTCRM POVs: Facebook Changes, September 2011RTC
 
RTCRM Perspectives September 2011
RTCRM Perspectives September 2011RTCRM Perspectives September 2011
RTCRM Perspectives September 2011RTC
 
Gamification Brownbag
Gamification BrownbagGamification Brownbag
Gamification BrownbagRTC
 
RTCRM Perspectives August 2011
RTCRM Perspectives August 2011RTCRM Perspectives August 2011
RTCRM Perspectives August 2011RTC
 
ICANN POV
ICANN POVICANN POV
ICANN POVRTC
 
RTCRM Perspectives May 2011
RTCRM Perspectives May 2011RTCRM Perspectives May 2011
RTCRM Perspectives May 2011RTC
 
RTCRM Perspectives April 2011
RTCRM Perspectives April 2011RTCRM Perspectives April 2011
RTCRM Perspectives April 2011RTC
 

Plus de RTC (20)

RTC Google Knowledge Graph POV June 2012
RTC Google Knowledge Graph POV June 2012RTC Google Knowledge Graph POV June 2012
RTC Google Knowledge Graph POV June 2012
 
RTC Perspectives, May 2012: Thank You, Star Trek
RTC Perspectives, May 2012: Thank You, Star TrekRTC Perspectives, May 2012: Thank You, Star Trek
RTC Perspectives, May 2012: Thank You, Star Trek
 
RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012
RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012
RTC POVs: Facebook Timeline for Pharma Brand Pages, April 2012
 
RTC POVs: FDA Warning Letter for Copaxone, March 2012
RTC POVs: FDA Warning Letter for Copaxone, March 2012RTC POVs: FDA Warning Letter for Copaxone, March 2012
RTC POVs: FDA Warning Letter for Copaxone, March 2012
 
RTC POVs: FDA Guidance on TV Ad Pre-Dissemination Review
RTC POVs: FDA Guidance on TV Ad Pre-Dissemination ReviewRTC POVs: FDA Guidance on TV Ad Pre-Dissemination Review
RTC POVs: FDA Guidance on TV Ad Pre-Dissemination Review
 
RTC Perspectives: February 2012
RTC Perspectives: February 2012RTC Perspectives: February 2012
RTC Perspectives: February 2012
 
FDA Warning Letters: Dr. Reddy's Labs, January 2012
FDA Warning Letters: Dr. Reddy's Labs, January 2012FDA Warning Letters: Dr. Reddy's Labs, January 2012
FDA Warning Letters: Dr. Reddy's Labs, January 2012
 
Dii POV: FDA Off-Label Guidance
Dii POV: FDA Off-Label GuidanceDii POV: FDA Off-Label Guidance
Dii POV: FDA Off-Label Guidance
 
Internet Radio for Marketers
Internet Radio for MarketersInternet Radio for Marketers
Internet Radio for Marketers
 
Patient Support Landscape
Patient Support LandscapePatient Support Landscape
Patient Support Landscape
 
FDA Warning Letters: Otsuka, October 2011
FDA Warning Letters: Otsuka, October 2011FDA Warning Letters: Otsuka, October 2011
FDA Warning Letters: Otsuka, October 2011
 
FDA Warning Letter: Busulfex Site
FDA Warning Letter: Busulfex SiteFDA Warning Letter: Busulfex Site
FDA Warning Letter: Busulfex Site
 
Strategy and Insights Brainstorming Guide
Strategy and Insights Brainstorming GuideStrategy and Insights Brainstorming Guide
Strategy and Insights Brainstorming Guide
 
RTCRM POVs: Facebook Changes, September 2011
RTCRM POVs: Facebook Changes, September 2011RTCRM POVs: Facebook Changes, September 2011
RTCRM POVs: Facebook Changes, September 2011
 
RTCRM Perspectives September 2011
RTCRM Perspectives September 2011RTCRM Perspectives September 2011
RTCRM Perspectives September 2011
 
Gamification Brownbag
Gamification BrownbagGamification Brownbag
Gamification Brownbag
 
RTCRM Perspectives August 2011
RTCRM Perspectives August 2011RTCRM Perspectives August 2011
RTCRM Perspectives August 2011
 
ICANN POV
ICANN POVICANN POV
ICANN POV
 
RTCRM Perspectives May 2011
RTCRM Perspectives May 2011RTCRM Perspectives May 2011
RTCRM Perspectives May 2011
 
RTCRM Perspectives April 2011
RTCRM Perspectives April 2011RTCRM Perspectives April 2011
RTCRM Perspectives April 2011
 

Dernier

Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Seta Wicaksana
 
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...ShrutiBose4
 
2024 Numerator Consumer Study of Cannabis Usage
2024 Numerator Consumer Study of Cannabis Usage2024 Numerator Consumer Study of Cannabis Usage
2024 Numerator Consumer Study of Cannabis UsageNeil Kimberley
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdfKhaled Al Awadi
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...ictsugar
 
Kenya’s Coconut Value Chain by Gatsby Africa
Kenya’s Coconut Value Chain by Gatsby AfricaKenya’s Coconut Value Chain by Gatsby Africa
Kenya’s Coconut Value Chain by Gatsby Africaictsugar
 
Case study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailCase study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailAriel592675
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyotictsugar
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Kirill Klimov
 
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCRashishs7044
 
Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionMintel Group
 
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent ChirchirMarketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchirictsugar
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044
 
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / NcrCall Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncrdollysharma2066
 
Call Us 📲8800102216📞 Call Girls In DLF City Gurgaon
Call Us 📲8800102216📞 Call Girls In DLF City GurgaonCall Us 📲8800102216📞 Call Girls In DLF City Gurgaon
Call Us 📲8800102216📞 Call Girls In DLF City Gurgaoncallgirls2057
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCRashishs7044
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menzaictsugar
 

Dernier (20)

Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...
 
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
 
2024 Numerator Consumer Study of Cannabis Usage
2024 Numerator Consumer Study of Cannabis Usage2024 Numerator Consumer Study of Cannabis Usage
2024 Numerator Consumer Study of Cannabis Usage
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
 
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North GoaCall Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
 
Kenya’s Coconut Value Chain by Gatsby Africa
Kenya’s Coconut Value Chain by Gatsby AfricaKenya’s Coconut Value Chain by Gatsby Africa
Kenya’s Coconut Value Chain by Gatsby Africa
 
Case study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailCase study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detail
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyot
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024
 
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
 
Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted Version
 
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent ChirchirMarketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchir
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
 
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / NcrCall Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
 
Call Us 📲8800102216📞 Call Girls In DLF City Gurgaon
Call Us 📲8800102216📞 Call Girls In DLF City GurgaonCall Us 📲8800102216📞 Call Girls In DLF City Gurgaon
Call Us 📲8800102216📞 Call Girls In DLF City Gurgaon
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
 

POV FDA Guidelines on Mobile

  • 1. New FDA Draft Guidance on Mobile Medical Apps Rebecca Johnson, Digital Integration & Innovation July 2011 Top-Level Points Summary On July 19, 2011, the U.S. Food and Drug Administration (FDA) issued a new draft  The FDA issued guidance on guidance detailing how the regulatory body defines, classifies and regulates “mobile mobile apps for medical use medical apps.” The new guidance expands upon the FDA’s previous definition of a  The FDA has established a two- medical device to include what the FDA defines as mobile medical apps. The FDA part definition of a mobile believes these mobile medical apps, which are increasingly common, pose the same medical app risks to patients as those posed by medical devices (e.g. EEG and MRI) and that the 1 FDA is therefore required to regulate mobile medical apps. As with all FDA draft  The FDA classifies three specific guidances, these guidelines do not establish legally enforceable responsibilities but subsets of mobile medical apps rather describe the regulatory agency’s current thinking and recommendations on (based strongly on the app’s the subject matter. Nevertheless, these guidelines should be taken seriously. intended use) as medical devices  Mobile medical apps that classify Key Information as medical devices should follow The FDA’s “Draft Guidance for Industry and Food and Drug Administration Staff – FDA guidance and regulations for Mobile Medical Applications” can be summarized into three main sections that state medical devices the FDA’s position on:  Definition of a Mobile Medical App  The agency has listed specific types of mobile apps it will not be  Scope of FDA Regulation Over Mobile Medical Apps monitoring  FDA Mobile Medical App Regulations and Controls  The FDA realizes these new In the new documentation, the FDA provides its definition of a mobile application guidelines may cause some (mobile app) as “a software application that can be executed (run) on a mobile confusion, and it encourages platform, or a web-based software application that is tailored to a mobile platform manufacturers of mobile medical but is executed on a server.” With this broad app definition in place, the FDA then apps to contact the Agency to lays out a two-part definition for a “mobile medical app” that it will use to evaluate determine the classification of what apps fall under its oversight. their mobile app  If needed, the FDA will expand 1. The mobile medical app must meet the FDA definition of a device: “an its current definition of a mobile instrument, apparatus, implement, machine, contrivance, implant, in vitro medical app and apply reagent… intended for use in the diagnosis or the cure, mitigation, regulations per this new treatment, or prevention of disease, or to affect the structure or any 2 definition function of the body of man.” 2. The mobile medical app must be either “used as an accessory to a regulated  In future guidelines, the FDA will medical device” or “transform a mobile platform into a regulated medical be addressing issues of wireless 3 device.” safety, quality systems and clinical decision support Most mobile apps will meet the first definitional requirement, as the FDA already considers application software a form of device. Therefore, the real qualifier will be the mobile app’s intended use, which the FDA states can be found in the app’s labeling claims, advertising materials, or in oral or written statements by manufacturers or their representatives. However, the FDA will only be applying its regulatory oversight to three types of mobile medical apps, because it believes these apps pose the same or similar risk to the public health as currently regulated medical devices. The three types of apps, listed below, are based on the app’s intended use. 1 “Draft Guidance for Industry and Food and Drug Administration Staff – Mobile Medical Applications” (page 5) 2 “Federal Food, Drug and Cosmetic Act (FD&C Act)” - Section 201(h) 3 “Draft Guidance for Industry and Food and Drug Administration Staff – Mobile Medical Applications” (page 7) Pg. 1
  • 2. 1. Apps that connect to a medical device for the purpose of A) controlling the device, or B) displaying, storing, analyzing or transmitting patient-specific medical device data (e.g. an app that controls the delivery of insulin on an insulin pump by transmitting signals to the pump) 2. Apps that transform the mobile platform into a medical device by using attachments, display screens or sensors or by including functionalities similar to those of currently regulated medical devices (e.g. an app that allows doctors to monitor brain activity by attaching EEG sensors to a mobile device) 3. Apps that allow the user to input patient-specific information and — using formulae or processing algorithms — output a patient-specific result, diagnosis or treatment recommendation to be used in clinical practice or to assist in making clinical decisions (e.g. an app that provides a questionnaire for collecting patient-specific lab results and computes the prognosis of a particular condition) If a mobile medical app falls into one of the above categories, its manufacturers are required to follow the medical device regulations established by the FDA. These medical device regulations and controls are broken up into three classifications (Class I, Class II and Class II). A mobile medical app’s classification will determine, among other things, the type of pre-marketing submission/application required for FDA clearance to market. In addition to stating the definition of a mobile medical app and what types of mobile medical apps it will regulate, the FDA has also defined categories of mobile apps it does not consider mobile medical apps and that are therefore not subject to draft guidance. This list includes apps that:  Are electronic “copies” of medical textbooks, teaching aids, or reference materials (e.g. an electronic version of the Physician’s Desk Reference or reference flash cards or slideshows of common conditions)  Are solely used to log, record, track, evaluate or make decisions or suggestions related to general health, lifestyle and wellness (e.g. dietary tracking logs, appointment reminders, exercise suggestions, etc.)  Automate general office operations with functionalities that include billing, inventory, appointments or insurance transactions (e.g. apps that determine billing codes or automate functions such as collecting patient histories or that enable insurance claims data collection)  Are generic aids that assist users but are not commercially marketed for a specific medical indication (e.g. apps that use the mobile platform for recording audio or note-taking)  Perform the functionality of an electronic health record system or personal health record system Implications and Action Items  Apps Already in Market: Review the FDA draft guidance closely. Determine if your app meets the FDA mobile medical app definition. If it does, work with your legal and regulatory teams to determine if it falls under the FDA’s regulatory oversight as a medical device and will need to follow the medical device regulations established by the FDA.  Apps Currently in Development: Review the FDA draft guidance closely. Discuss with your regulatory and legal departments the potential impact these new regulations may have on your app with a particular eye to timelines, budget and functionality.  Planning an App: Review the FDA draft guidance closely. Ascertain if your proposed app meets the FDA mobile medical app definition. If it will be under the FDA’s regulatory oversight, then follow the medical device regulations established by the FDA.  Potential for More Guidelines: While the FDA has been very specific with its definition of what is and isn’t a mobile medical app, in the draft guidance the Agency will continue to monitor the performance of other mobile apps that are outside this guidance and determine whether additional or different actions are necessary to protect the public health. For more insights into applying FDA regulations to digital marketing, see: http://rtcrm.com/whitepapers/ Pg. 2